Table 1 Summary of the oxidative stress biomarkers studied in different specimens of IPF patients
Biological specimens | Comparison (n) | Oxidative stress biomarkers | Ref. |
|---|---|---|---|
Plasma | IPF (36) vs Ctrl (31) | TEAC↓; PSH↔; MDA↑ | 21 |
Plasma | IPF/UIP (10) vs Ctrl (10) | Hydroperoxides↑ | 22 |
Plasma and urine | IPF (29) vs Ctrl (6) | Pl-isoprostanes↑; Ur-H2O2↔ | 24 |
Plasma and urine | IPF at rest (29) vs IPF after physical exercise (29) | Pl-isoprostanes↔; Pl-TAC↓; Ur-isoprostanes↑; Ur-H2O2↔ | 24 |
Serum | IPF (16) vs Ctrl (17) | 8-Isoprostane↑ | 25 |
Blood | IPF (22) vs Ctrl (29) | GSH↓; GSSG↑; GSH/GSSG↓ | 26 |
Serum | IPF (43) vs Ctrl (30) | Hydroperoxides↑ | 27 |
Serum | AE-IPF (13) vs IPF (30) | Hydroperoxides↑ | 27 |
Plasma | IIP (31-9IPF) vs Ctrl (33) | TOS↑; OSI↑; TAS↔ | 28 |
Blood and plasma | IPF (10) vs Ctrl (9) | Bl-GSH↓;Bl-GSSG↔; Bl-Vitamin C↔ Pl-Uric acid↔; Pl-TEAC↓ | 29 |
Breath | ILD (34-13IPF) vs Ctrl (9) | Ethane ↑ | 30 |
Sputum | IPF (16) vs Ctrl (15) | GSH↓ | 31 |
EBC | IPF (16) vs Ctrl (15) | H2O2↑; 8-isoprostane↑ | 33 |
EBC | IPF (38) vs Ctrl (14) | MDA↔ | 34 |
EBC | IPF (20) vs Ctrl (20) | 3NT↑; NOx↔; Proteins↑; 8-isoprostane↑;H2O2↔; | 35 |
EBC | IPF (6) vs lung cancer (6) | 8-isoPGF2α↑ | 36 |
ELF | IPF (44) vs Ctrl (11) | MPO↑ | 42 |
ELF | IPF (15) vs Ctrl (19) | tGSH↓; GSH/(GSH + GSSG) ↔ | 46 |
ELF | IPF (10) vs Ctrl (10) | tGSH↓; rGSH↓ | 49 |
ELF | IPF (17) vs Ctrl (14) | tGSH↓ | 50 |
BALF | IPF smokers (8) vs Ctrl smokers (6) | Protein carbonyls↔ | 52 |
BALF | IPF nonsmokers (9) vs Ctrl nonsmokers (14) | Protein carbonyls↑ | 52 |
BALF | IPF (9) vs Ctrl (5) | Protein carbonyls↑ | 54 |
BALF | IPF (13) vs Ctrl (5) | Protein carbonyls↑ | 55 |
BALF | IPF (15) vs Ctrl (8) | Protein carbonyls↑ | 56 |
BALF | s-IPF (17) vs f-IPF (10) | isocitrate dehydrogenase↓; peroxiredoxin 1↓; antithrombin III↓; complement factor B↓ | 57 |
BALF | IPF (17) vs Ctrl (14) | tGSH↔ | 50 |
BALF | IPF (36) vs Ctrl (31) | TEAC↓; GSH↓; GSSG↔; PSH↓; MDA↑ | 21 |
BALF | IPF (17) vs Ctrl (27) | GSH↔; Uric Acid↑; Ascorbic Acid↑; α-tocopherol↑; retinol↑; GSSG↑; F2-isoprostanes↔ | 58 |
BALF | IPF (16) vs Sarcoidosis (55) | 8-isoprostane↓ | 25 |
Lung tissue | IPF (10) vs Ctrl (10) | ECSOD↔ | 59 |
Lung tissue | IPF fibrotic areas vs IPF normal areas | ECSOD↓ | 59 |
Lung tissue | IPF (10) vs Ctrl (10) | PrxII ↔ | 60 |
Lung tissue | IPF fibrotic areas vs IPF normal areas | PrxII↓; 3-NT↓ | 60 |
Lung tissue | IPF (7) vs Ctrl (7) | NRF2↔; SRX1↑ | 61 |
Lung tissue | IPF hyperplastic epithelium vs IPF normal epithelium | NRF2↑; KEAP1↑ | 61 |
Lung tissue | IPF (14) vs Ctrl (10) | GST ↓; Hp↓ | 63 |
Lung tissue | IPF (14) vs fNSIP (8) | PRDX6↓; TPxB↓; | 63 |
Lung tissue | IPF (13) vs Ctrl (15) | Cys↑; Gly↑; Glu↑ | 64 |